|
By Jess Halliday
10/3/2005
- FDA’s record on qualified health claims approvals is causing
companies to re-think their petitions. In the light of recent decisions
the FDA has handed down, The Solae Company has decided to temporarily
withdraw its soy/cancer prevention claim.
A spokesperson for Solae told NutraIngredients-USA.com
that the company first submitted its petition for a claim on the
link between soy and cancer prevention in April 2004. As is the
case with a number of other submissions, a decision has been delayed
on a number of occasions.
But despite the industry's frustration over such delays, Solae's
withdrawal is not a sign of total disillusionment with the process.
Rather, it has signaled that it will be making some improvements
to its submission, after having studied the nature of other recent
petitions and approvals. This, it believes, will give it a better
chance of success.
"Our decision has nothing to
do with our confidence in the science," said Dr Greg Paul,
director of health and nutrition for The Solae Company. "We
have an improved understanding of the process and have decided to
withdraw the petition and re-structure it so it will be in-line
with the FDA's current qualified health claim process."
No specific time-line has been set
for the resubmission, but Solae has said that the 60-study strong
body of evidence supporting the link between soy consumption and
a reduced risk of developing several types of cancer continues to
grow.
Most recently, the current issue
of the Journal of the American Medical Association contains a University
of Texas study indicating that eating foods containing phytoestrogens,
including soya products, reduces the risk of developing lung cancer
even in smokers.
“The company's objective in
filing this petition was to enable research-based health information
to be made more readily available to consumers,” said the
company in a statement.
In an interview with NutraIngredients-USA.com
in June, Kathy Ellwood, director of nutrition programs and labeling
at the FDA's Center for Food Safety and Applied Nutrition, said
that the approval delays are the result of “very limited resources”.
http://www.fda.gov/ohrms/dockets/dockets/04q0151/04Q-0151-emc0002-vol4.doc
|